Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for generic drug applications
Does Allergan's Saint Regis Mohawk Tribe transactional move "rip off consumers"? Does Allergan's Saint Regis Mohawk Tribe transactional move "rip off consumers"? Reviewed by Annsley Merelle Ward on Monday, September 18, 2017 Rating: 5
Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law? Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law? Reviewed by Annsley Merelle Ward on Monday, March 16, 2015 Rating: 5
Letter from AmeriKat: Judge Koh declares Takeda takes it too far with Mylan Dexilant declaration Letter from AmeriKat: Judge Koh declares Takeda takes it too far with Mylan Dexilant declaration Reviewed by Annsley Merelle Ward on Monday, August 25, 2014 Rating: 5
Wrongly excluded, rightly compensated: is "but for" the best solution? Wrongly excluded, rightly compensated: is "but for" the best solution? Reviewed by Jeremy on Tuesday, November 06, 2012 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.